Skip to main content

Advertisement

Table 1 Characteristics of the included trials

From: Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis

Trial Number Setting Trial duration ICU Population Intervention Comparator Outcomes
Inclusion criteria Exclusion criteria
Youness et al. [20] 33 Single-centre US 24 months Mixed Intubated mechanically ventilated patients with new-onset (<48 h) atelectasis CF, uncontrolled asthma, COPD, pneumothorax, pleura effusion, tumor-associated atelectasis, severe hypoxemia, hemodynamic instability, allergy to dornase alfa, use of nebulized acetylcysteine and pregnancy Nebulized dornase alfa 2.5 mg twice daily in 7 days or until resolution of atelectasis (1) Placebo (isotonic saline) same volume, dosage, and duration of treatment Mortality
(2) Hypertonic saline (same volume, dosage, and duration of treatment)
Zitter et al. [19] 30 Single-centre US 12 months Mixed Mechanically ventilated patients aged >18 years with new-onset (<24 h) atelectasis Quadriplegia, chronic ventilator dependence, pneumothorax, frank hemoptysis, elevated intracranial pressure, pregnancy or active nursing, concurrent use of other investigational drugs, and allergy to dornase alfa, Chinese hamster ovary-derived biologics or other components of the active component Nebulized dornase alfa 2.5 mg twice daily until extubation, death or transfer (maximum 30 days) Placebo (isotonic saline) same volume, dosage, and duration of treatment Mortality
  1. CF Cystic fibrosis, COPD chronic obstructive pulmonary disease